6 Allergy Headlines You Missed in September 2025

As September 2025 wraps up, advances in clinical research are offering fresh insights into allergy treatment and management. Regeneron’s allergen-blocking antibodies for cat and birch allergies achieved phase 3 success, while the phase 2 VIBRANT trial demonstrated verekitug’s lasting benefits for patients with chronic rhinosinusitis and nasal polyps.

Other findings included Prota Therapeutics’ PRT120 oral immunotherapy earning recognition for its ability to induce long-term remission in peanut allergy and real-world evidence supporting the use of epinephrine nasal spray as a needle-free rescue option for anaphylaxis. This allergy month in review captures the top 6 allergy news storiin September.

New Phase 3 & 4 Data in the Allergy Field

First in Class Cat, Birch Allergen Blockers Succeed in Phase 3 Trials

Regeneron’s allergen-specific antibody therapies achieved primary endpoints in 2 phase 3 trials for cat and birch allergies, significantly reducing ocular itch, conjunctival redness, and skin prick reactivity. In the cat allergy trial, the FelD1-blocking antibody combination REGN1908/1909 reduced itch by 52%, redness by 39%, and skin reactivity by 44% 1 week after treatment, with even greater benefit in FelD1-driven cases. The birch allergy trial using REGN5713/5715 showed similar improvements, reducing itch by 51% and redness by 46%. Both therapies were well-tolerated, with no serious adverse events, supporting their potential as rapid, durable alternatives to allergy shots.

Phase 4 Trial Confirms Endoscopic Sinus Surgery Efficacy for Chronic Rhinosinusitis

A phase 4 randomized trial (MACRO) confirmed endoscopic sinus surgery (ESS) as the most effective treatment for chronic rhinosinusitis (CRS), significantly improving symptoms compared with clarithromycin or placebo based on SNOT-22 scores. ESS showed a mean difference of -18.13 versus clarithromycin and -20.44 versus placebo (P <.0001).

In contrast, clarithromycin offered no significant benefit over placebo, questioning its long-term use in CRS management. Among 514 participants, adverse events were few and nonfatal. Investigators emphasized that these findings support ESS as a superior intervention.

Phase 2 data

Phase 2 VIBRANT Trial: Verekitug Improves Nasal Polyps in Chronic Rhinosinusitis

The phase 2 VIBRANT trial demonstrated that verekitug, a monoclonal antibody targeting the TSLP receptor, significantly improved outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Verekitug met its primary endpoint, reducing endoscopic nasal polyp scores by –1.8 at week 24 (P < .0001), and achieved secondary endpoints, including improvements in nasal congestion, sinus opacification, and symptom scores, while reducing the need for corticosteroids or surgery. The treatment, given every 12 weeks, was well-tolerated with no serious adverse events.

EAACI Recognizes the Efficacy of PRT120 OIT

PRT120 OIT Wins EAACI Prize for Durable Peanut Allergy Remission

The phase 2b PPOIT-003 long-term study showed that PRT120 peanut oral immunotherapy induced durable remission, allowing children to safely consume peanuts without ongoing daily dosing. Three-year follow-up data revealed more than 90% of children in remission maintained regular intake without moderate or severe reactions, contrasting with higher reaction rates among desensitized participants. These findings earned Prota Therapeutics the EAACI Prize at the 2025 Annual Congress, underscoring remission as a more meaningful treatment goal than desensitization.

Other Notable Findings in the Allergy Space

Avapritinib Demonstrates Durable Improvements in Indolent Systemic Mastocytosis Symptoms, QoL

Updated data from the PIONEER trial extension showed that avapritinib 25 mg once daily provided durable improvements in symptoms and quality of life for patients with indolent systemic mastocytosis through 96 weeks. Patients reported sustained reductions in Total Symptom Score and improvements across all 11 symptom domains, with notable relief in itching, flushing, fatigue, and skin spots. Treatment adherence was high, and safety findings remained consistent with earlier reports, with low rates of severe or treatment-discontinuing adverse events.

Epinephrine Nasal Spray as Effective as Injection for Anaphylaxis in Real-World Data

Real-world data show epinephrine nasal spray (neffy) is as effective as injections for treating anaphylaxis, with a single 2 mg dose achieving an 89.2% success rate in 545 patients, comparable to injection outcomes (88.9%). The FDA approved neffy in 2024 for type 1 allergic reactions, including anaphylaxis, in patients aged 4 years and older, providing a needle-free alternative to auto-injectors. Investigators noted high effectiveness across oral food challenges and allergen immunotherapy, with most patients requiring only one dose.